A novel series of C1 inhibitors

PubMed, the Internet portal of biomedical and life sciences literature, indexed an interesting article, entitled “A novel series of arylsulfonylthiophene-2-carboxamidine inhibitors of the complement component C1s” (Bioorg Med Chem Lett. 2006 Feb 2). Authors are Subasinghe NL, Travins JM, Ali F et al. from the Johnson & Johnson Pharmaceutical Research and Development, L.L.C., Exton, USA. A series of arylsulfonylthiophene-2-carboxamidine inhibitors of C1s were synthesized and evaluated for C1s inhibitory activity. Inhibiting the classical pathway of complement activation by attenuating the proteolytic activity of the serine protease C1s is a potential strategy for the therapeutic intervention in disease states such as hereditary angioedema, ischemia-reperfusion injury, and acute transplant rejection. To access the full abstract of the article, click here.